After steering Lundbeck through buyouts, layoffs and big approval, Deborah Dunsire will step down

Sea­soned biotech CEO Deb­o­rah Dun­sire is re­tir­ing from Lund­beck af­ter five years, mak­ing room for Charl van Zyl to step in as pres­i­dent and CEO by Oc­to­ber.

The an­nounce­ment for Dun­sire’s planned de­par­ture fol­lows a string of pos­i­tive news out of the Dan­ish drug­mak­er, in­clud­ing an FDA ap­proval for its Ot­su­ka-part­nered an­tipsy­chot­ic Rex­ul­ti for ag­i­ta­tion as­so­ci­at­ed with de­men­tia due to Alzheimer’s dis­ease — a po­ten­tial block­buster in­di­ca­tion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN